Changes in cervical keratinocyte gene expression associated with integration of human papillomavirus 16.

Episomal integration is a critical event in human papillomavirus (HPV)-related oncogenesis, although little information is currently available concerning the effect of integration on the host transcriptome. We have used expression microarrays to investigate the effect of integration of HPV16 on gene expression in cervical keratinocytes, using the unique cell line model W12. W12 was generated from a cervical low-grade squamous intraepithelial lesion "naturally" infected with HPV16 and at low passage contains approximately 100 HPV16 episomes/cell. With passage in vitro, integration of viral episomes is associated with the development of phenotypic and genomic abnormalities resembling those seen in cervical neoplastic progression in vivo. We have used the Affymetrix U95A oligonucleotide array that contains probes for 12,600 human transcripts and have identified 85 genes from a range of host cell pathways that show changes in expression levels after integration of HPV16. Whereas some of the genes have previously been implicated in HPV-related oncogenesis in vivo, we have also identified a range of genes not previously described as being involved in cervical neoplastic progression. Interestingly, integration is associated with up-regulation of numerous IFN-responsive genes, in comparison with a baseline of episomally infected cells. These genes include p48, a component of the primary regulator of the IFN response pathway, IFN-stimulated gene factor 3. The physical state of high-risk HPV may substantially influence the response to IFN in infected keratinocytes.

[1]  Y. Ito,et al.  Studies on a New Human Cell Line (SiHa) Derived from Carcinoma of Uterus. I. Its Establishment and Morphology 1 , 1970, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[2]  R. Pattillo,et al.  Tumor antigen and human chorionic gonadotropin in CaSki cells: a new epidermoid cervical cancer cell line. , 1977, Science.

[3]  M. Karin,et al.  Trans‐activation of an upstream early gene promoter of bovine papilloma virus‐1 by a product of the viral E2 gene. , 1987, The EMBO journal.

[4]  M. Stanley,et al.  Properties of a non‐tumorigenic human cervical keratinocyte cell line , 1989, International journal of cancer.

[5]  M. Wagatsuma,et al.  Analysis of integrated human papillomavirus type 16 DNA in cervical cancers: amplification of viral sequences together with cellular flanking sequences , 1990, Journal of virology.

[6]  J. G. van den Tweel,et al.  Human papillomavirus type 16 transcripts expressed from viral-cellular junctions and full-length viral copies in CaSki cells and in a cervical carcinoma. , 1991, Virology.

[7]  H. zur Hausen,et al.  Human papillomavirus type 16 (HPV 16) gene expression and DNA replication in cervical neoplasia: analysis by in situ hybridization. , 1992, Virology.

[8]  C. Burrell,et al.  Transcription patterns of human papillomavirus type 16 in genital intraepithelial neoplasia: evidence for promoter usage within the E7 open reading frame during epithelial differentiation. , 1992, The Journal of general virology.

[9]  M. Stanley,et al.  Characterization and functional analysis of the expression of intercellular adhesion molecule-1 in human papillomavirus-related disease of cervical keratinocytes. , 1993, The American journal of pathology.

[10]  S Wacholder,et al.  Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. , 1993, Journal of the National Cancer Institute.

[11]  P. V. D. van de Kerkhof,et al.  Demonstration of skin‐derived antileukoproteinase (skalp) and its target enzyme human leukocyte elastase in squamous cell carcinoma , 1994, The Journal of pathology.

[12]  A. Ullrich,et al.  The secreted tumor-associated antigen 90K is a potent immune stimulator. , 1994, The Journal of biological chemistry.

[13]  A. García-Carrancá,et al.  Genome amplification of human papillomavirus types 16 and 18 in cervical carcinomas is related to the retention of E1/E2 genes , 1994, International journal of cancer.

[14]  L. Chow,et al.  Human papillomavirus type 11 E2 proteins repress the homologous E6 promoter by interfering with the binding of host transcription factors to adjacent elements , 1994, Journal of virology.

[15]  C. Delgado,et al.  Insulin-like growth factor II mediates epidermal growth factor-induced mitogenesis in cervical cancer cells. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[16]  L. Brinton,et al.  The epidemiology of cervical carcinogenesis , 1995, Cancer.

[17]  E. Schröck,et al.  Advanced‐stage cervical carcinomas are defined by a recurrent pattern of chromosomal aberrations revealing high genetic instability and a consistent gain of chromosome arm 3q , 1997, Genes, chromosomes & cancer.

[18]  S. J. Kim,et al.  Physical status and expression of HPV genes in cervical cancers. , 1997, Gynecologic oncology.

[19]  H. Egami,et al.  Immunohistochemical expression of SKALP/elafin in squamous cell carcinoma of the oesophagus. , 1997, British Journal of Cancer.

[20]  C. H. Buckley,et al.  Aetiology, pathogenesis, and pathology of cervical neoplasia. , 1998, Journal of clinical pathology.

[21]  N. Ordóñez.  Thrombomodulin expression in transitional cell carcinoma. , 1998, American journal of clinical pathology.

[22]  P. Lazo,et al.  The molecular genetics of cervical carcinoma , 1999, British Journal of Cancer.

[23]  P. Howley,et al.  Repression of the Integrated Papillomavirus E6/E7 Promoter Is Required for Growth Suppression of Cervical Cancer Cells , 2000, Journal of Virology.

[24]  D. Lockhart,et al.  Mitotic misregulation and human aging. , 2000, Science.

[25]  R. Young,et al.  Cervical Epidermal Growth Factor‐Receptor (EGF‐R) and Serum Insulin‐Like Growth Factor II (IGF‐II) Levels are Potential Markers for Cervical Cancer 1 , 2000, American journal of reproductive immunology.

[26]  L. Laimins,et al.  Microarray Analysis Identifies Interferon-Inducible Genes and Stat-1 as Major Transcriptional Targets of Human Papillomavirus Type 31 , 2000, Journal of Virology.

[27]  D. Bostwick,et al.  Human acid ceramidase is overexpressed but not mutated in prostate cancer , 2000, Genes, chromosomes & cancer.

[28]  C. Li,et al.  Analyzing high‐density oligonucleotide gene expression array data , 2001, Journal of cellular biochemistry.

[29]  T. Ishizaki,et al.  Increased secretory leukoprotease inhibitor in patients with nonsmall cell lung carcinoma , 2000, Cancer.

[30]  M. Stanley,et al.  Early genetic events in HPV immortalised keratinocytes , 2001, Genes, chromosomes & cancer.

[31]  C. Woodworth,et al.  Papillomavirus Type 16 Oncogenes Downregulate Expression of Interferon-Responsive Genes and Upregulate Proliferation-Associated and NF-κB-Responsive Genes in Cervical Keratinocytes , 2001, Journal of Virology.

[32]  C. Lundsteen,et al.  Comparative genomic hybridization reveals non-random chromosomal aberrations in early preinvasive cervical lesions. , 2001, Cancer genetics and cytogenetics.

[33]  L. Laimins,et al.  Cellular Changes Induced by Low-Risk Human Papillomavirus Type 11 in Keratinocytes That Stably Maintain Viral Episomes , 2001, Journal of Virology.

[34]  E. Blennow,et al.  Physical State of HPV16 and Chromosomal Mapping of the Integrated Form in Cervical Carcinomas , 2001, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[35]  M. Kuo,et al.  The anti-apoptotic role of interleukin-6 in human cervical cancer is mediated by up-regulation of Mcl-1 through a PI 3-K/Akt pathway , 2001, Oncogene.

[36]  R. Freshney.  Culture of epithelial cells , 2002 .

[37]  Keith Wilson,et al.  Silence of chromosomal amplifications in colon cancer. , 2002, Cancer research.

[38]  M. Stanley.  Culture of Human Cervical Epithelial Cells , 2002 .